Search This Blog

Thursday, January 29, 2009

LIPID LOWERING MAY DECREASE NEED FOR PDR IN DIABETICS

A body of evidence supports a role for lipid-modifying therapy in reducing the diabetic retinopathy endpoints. Results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study show beneficial effects of fenofibrate in reducing the requirement for laser therapy, and particularly in preventing disease progression in patients with pre-existing diabetic retinopathy.

No comments:

Post a Comment

Leave a Comment or Question: